Merck (NYSE: MRK) announced positive topline results from its Phase 3 ATLAS-UC induction-only study evaluating tulisokibart, an investigational monoclonal antibody ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE